METABOLIC SYNDROME: PATHOPHYSIOLOGY OF INSULIN RESISTANCE AND VISCERAL ADIPOSITY, DIAGNOSTIC CRITERIA, CARDIOMETABOLIC RISK, AND EVIDENCE-BASED MANAGEMENT STRATEGIES

Abstract

Background: Metabolic syndrome (MetS) is a cluster of interconnected cardiometabolic risk factors—central obesity, insulin resistance, hyperglycemia, dyslipidemia (hypertriglyceridemia and low HDL-cholesterol), and hypertension—that collectively confer a 2–3-fold increased risk of type 2 diabetes mellitus (T2DM), a 1.5–2.0-fold increased risk of atherosclerotic cardiovascular disease (ASCVD), and substantially elevated risks of non-alcoholic steatohepatitis (NASH), polycystic ovary syndrome, obstructive sleep apnea, and certain cancers. The global prevalence of MetS is estimated at 20–25% of adults worldwide—approximately one billion people—and is projected to increase in parallel with the global obesity pandemic. Insulin resistance and excess visceral adipose tissue (VAT) function as the central pathophysiological drivers linking the individual components of the syndrome through shared molecular mechanisms involving ectopic lipid deposition, adipokine dysregulation, chronic low-grade inflammation, and hypothalamic-pituitary-adrenal axis dysregulation.

Objective: To provide a comprehensive, evidence-based review of the pathophysiology of metabolic syndrome, encompassing the molecular mechanisms of insulin resistance and visceral adiposity, the evolution and comparison of diagnostic criteria, the epidemiology and cardiometabolic risk implications, and the evidence base for lifestyle and pharmacological management strategies.

Methods: A systematic review of eight primary peer-reviewed sources was conducted, including original mechanistic studies, prospective cohort studies, large randomized clinical trials, meta-analyses, and authoritative clinical guidelines published between 2001 and 2024.

Results: Visceral adipose tissue (VAT) releases excess free fatty acids (FFA), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and resistin, while reducing adiponectin secretion—collectively impairing insulin receptor signaling through IRS-1 serine phosphorylation and activating hepatic de novo lipogenesis. The Joint Interim Statement (2009) harmonized five sets of diagnostic criteria into a unified definition requiring any three of five components. Intensive lifestyle intervention (7% weight loss + 150 min/week moderate exercise) reduces T2DM incidence by 58% in high-risk individuals with MetS (Diabetes Prevention Program). High-intensity statin therapy plus renin-angiotensin system blockade constitute the pharmacological cornerstones of ASCVD risk reduction in established MetS.